Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 2001 September;45(3) > The Quarterly Journal of Nuclear Medicine 2001 September;45(3):269-73

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

  PET IN ONCOLOGY
Guest Editor: I. Carrio
FREEfree


The Quarterly Journal of Nuclear Medicine 2001 September;45(3):269-73

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between Non-Hodgkin’s Lymphoma and Hodgkin’s disease

Spaepen K., Mortelmans L.

From the Department of Nuclear Medicine University Hospitals Gasthuisberg and Catholic University of Leuven, Leuven, Belgium


Full text temporarily not available online. Contact us  


Flu­o­rine-18flu­o­rod­e­ox­y­glu­cose posi­tron emis­sion tomog­raphy ([18F]FDG-PET) has ­become a ­very ­useful tech­nique for the ­therapy mon­i­toring of ­patients ­with lym­phoma. It pro­vides ­unique infor­ma­tion ­about the meta­bolic ­behavior of the dis­ease inde­pen­dent of mor­pho­log­ical cri­teria. In ­recent ­years, [18F]FDG-PET has ­proven to be a tech­nique ­with ­high sen­si­tivity for the detec­tion of ­residual ­tumor. There­fore, [18F]FDG-PET ­seems to be the ­ideal ­tool for the eval­u­a­tion of treat­ment ­response. How­ever, ­most ­recent pub­lished ­studies ­included ­both HD and NHL, ­although [18F]FDG-PET ­scan ­results in ­Hodgkin’s dis­ease (HD) has a dif­ferent ­impact ­than in Non ­Hodgkin’s Lym­phoma (NHL). In ­this ­paper, we sum­marize our find­ings on the ­role of [18F]FDG-PET in the ­therapy eval­u­a­tion of lym­phoma ­patients in a ­large ­group of ­patients and high­light the dif­fer­ences ­between the inter­pre­ta­tions of the ­results of HD and NHL ­patients. ­Finally, a ­strategy for the imple­men­ta­tion of [18F]FDG-PET in the man­age­ment of lym­phoma ­patients is pro­posed.

top of page

Publication History

Cite this article as

Corresponding author e-mail